Affymetrix of Santa Clara, Calif., has received US Patent No. 6,858,711, “Labeling reagents.” The invention provides a simplified method for identifying differences in nucleic acid abundances, for example expression levels, between two or more samples. The invention also provides a method of end-labeling a nucleic acid. In one embodiment, the method involves enzymatically ligating an oligonucleotide to a nucleic acid. For example, where the nucleic acid is an RNA, a labeled oligoribonucleotide can be ligated using an RNA ligase.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.